Key Takeaways
- Clinical Bottom Line
- What Changed
- Treat-to-Target
- Endoscopy Questions That Change Management
Clinical Bottom Line
Moderate-to-severe ulcerative colitis has moved beyond a slow step-up mindset. Current AGA and ACG guidance supports earlier use of effective advanced therapies, therapy selection based on prior exposure and risk, and objective monitoring with biomarkers and endoscopic healing. The endoscopist’s job is to define severity, document healing, and identify complications or mimics that change treatment.
| Clinical Scenario | Current Practical Direction | Endoscopy Role |
|---|---|---|
| Advanced therapy naive | Consider higher-efficacy options early rather than cycling prolonged steroids or low-yield step-up therapy. | Document extent, severity, Mayo endoscopic activity, and baseline dysplasia considerations. |
| Prior TNF exposure | Choice depends on prior response, immunogenicity, safety profile, urgency, and route preference. | Confirm active inflammatory disease before switching for symptoms alone. |
| IL-23 pathway options | Risankizumab, guselkumab, and mirikizumab are now part of mainstream moderate-to-severe UC positioning. | Set objective targets before induction so the follow-up exam answers a treatment question. |
| Symptom improvement | Do not stop at symptom response. Use fecal calprotectin, CRP when helpful, and endoscopic reassessment. | Endoscopic healing is a major long-term target, while histology can add risk context. |
| Steroid dependence | Treat steroid dependence as treatment failure, not as a maintenance strategy. | Look for severe activity, CMV when appropriate, and alternative diagnoses in refractory cases. |
What Changed
The therapeutic menu has expanded quickly. Anti-TNF therapy, vedolizumab, ustekinumab, S1P modulators, JAK inhibitors, and IL-23 pathway agents all have roles, but they are not interchangeable. The AGA living guideline groups options by expected efficacy and supports earlier advanced therapy use in moderate-to-severe disease. The 2025 ACG update also places IL-23p19 inhibitors squarely into induction therapy recommendations.
For practicing gastroenterologists, the question is less “what is newest?” and more “what is the best first serious therapy for this patient’s risk profile?” A young patient with severe endoscopic disease, steroid exposure, and hospitalization risk is different from a stable outpatient with moderate disease and strong route preferences. Prior biologic exposure, thrombotic risk, age, infection risk, pregnancy plans, cancer history, payer rules, and speed of onset all matter.
Treat-to-Target
Clinical remission is important, but it is not enough. A modern UC follow-up plan should combine symptoms, biomarkers, and endoscopic assessment. Fecal calprotectin is useful because it can flag residual inflammation before the next scope. Endoscopic healing remains a central target because persistent ulceration predicts relapse, hospitalization, corticosteroid exposure, and colectomy risk.
Histologic healing is increasingly discussed, but it should not be treated as the only target in routine practice. It adds prognostic information, especially when symptoms and endoscopy look reassuring, but therapy changes should still be individualized. A rigid histology-only approach can lead to overtreatment if the rest of the clinical picture is ignored.
Endoscopy Questions That Change Management
The most useful endoscopy report answers treatment questions. How far does disease extend? Is there deep ulceration? Is the rectum involved? Is the distribution consistent with UC, or does it raise concern for Crohn’s disease, infection, ischemia, medication injury, or segmental colitis associated with diverticulosis? In severe or steroid-refractory disease, biopsies for CMV can matter. In long-standing colitis, dysplasia surveillance is a separate but related quality issue.
Follow-up endoscopy should be timed to the decision being made. If the patient is clinically better after induction, the follow-up question is whether mucosa healed enough to stay the course. If the patient is not better, the question is whether active inflammation is still present, whether drug exposure is inadequate, or whether symptoms are being driven by a noninflammatory process.
How To Apply This In Practice
- Before starting advanced therapy, document disease extent, severity, steroid exposure, infections, vaccination gaps, and risk factors that influence drug choice.
- Use fecal calprotectin and symptoms for interval monitoring, but keep endoscopic healing in the treatment plan.
- Avoid prolonged steroid cycling while waiting for multiple low-efficacy steps to fail.
- In apparent refractory disease, confirm active inflammation before switching therapy solely for symptoms.
- Use the endoscopy report to answer the treatment question, not just to describe “colitis.”
Selected Sources
- AGA living guideline for moderate-to-severe ulcerative colitis
- ACG Clinical Guideline Update: Ulcerative Colitis in Adults
Clinical update for gastroenterologists and endoscopists. Reviewed May 2026.
